Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21

Articles

19304 items
12:00 AM, Aug 09, 1993  |  BioCentury | Product Development

Somatogen finally completes Phase Ib

Somatogen finally completes Phase Ib Just eight days after filing for a $40 million convertible exchangeable preferred stock offering, Somatogen Inc. announced that it had completed its Phase Ib study of rHb1.1 recombinant hemoglobin in...
12:00 AM, Aug 09, 1993  |  BioCentury | Product Development

Focused on adjuvant development

Focused on adjuvant development Although adjuvant programs have been spawned widely across the vaccine R&D field, only three companies are primarily focused on adjuvant development. The following summarizes those three programs. CytRx Corp. Through its Vaxcel...
12:00 AM, Aug 09, 1993  |  BioCentury | Product Development

Adjuvants key to biotech vaccines

A decade ago, interest in vaccines languished as liability issues drove most companies out of the business. But the resolution of those issues, the advent of AIDS and the return of tuberculosis have stimulated renewed...
12:00 AM, Aug 09, 1993  |  BioCentury | Product Development

A glossary of adjuvants

A glossary of adjuvants Non-proprietary Alum QS-21 Stimulon (Cambridge Biotech) - derived from soapbark tree, Quillaja saponaria Optivax (CytRx) - copolymer emulsion MPL (Ribi ImmunoChem) - monophosphoryl lipid A, a modified form of lipid A derived from bacterial endotoxin TLC A-60...
12:00 AM, Aug 09, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Gene therapy plays Furman Selz analyst Bruce Schackman said gene therapy is an exciting area because there is little competition from established drug companies; and because each company is developing a drug delivery platform with a...
12:00 AM, Aug 09, 1993  |  BioCentury | Politics, Policy & Law

BST foes win more time to lobby

BST foes win more time to lobby WASHINGTON - Congressional opponents of bovine somatotropin, who used parliamentary wrangling over the budget reconciliation to legislate a 90-day moratorium on BST sales, hope to continue their lobbying...
12:00 AM, Aug 02, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Somatogen Inc. (SMTG) Alex. Brown & Sons analyst David Webber lowered his rating to "neutral" from "buy" in reaction to new information on side effects from SMTG's rHb1.1 recombinant blood substitute published in the company's...
12:00 AM, Aug 02, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Cephalon Inc. (CEPH) Meg Malloy of Needham & Co. initiated coverage with a "buy" rating. She said CEPH's ability to develop novel small molecules to promote the survival of neurons may provide it with a...
12:00 AM, Aug 02, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Immunex Corp. (IMNX) Stuart Weisbrod of Merrill Lynch lowered his intermediate-term rating to "neutral" from "above average" after the company's second-quarter results indicated that Lederle oncology sales were weaker than expected and expenses were higher...
12:00 AM, Aug 02, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Genzyme Corp. (GENZ) Hancock Institutional Equity Services analyst Margaret McGeorge said there were no surprises in Genzyme Corp.'s second-quarter numbers, with the company hitting its $31 million target for sales of Ceredase for Gaucher...

Pages